Skip to main content
Top
Published in: BMC Infectious Diseases 1/2021

Open Access 01-12-2021 | Tuberculosis | Research article

Risk factors for mortality among patients diagnosed with multi-drug resistant tuberculosis in Uganda- a case-control study

Authors: Enock Kizito, Joseph Musaazi, Kenneth Mutesasira, Fred Twinomugisha, Helen Namwanje, Timothy Kiyemba, Debora B. Freitas Lopez, Nicholas Sebuliba Nicholas, Abel Nkolo, Estella Birabwa, Seyoum Dejene, Stella Zawedde-Muyanja

Published in: BMC Infectious Diseases | Issue 1/2021

Login to get access

Abstract

Background

The World Health Organization (WHO) End TB strategy aims to reduce mortality due to tuberculosis (TB) to less than 5% by 2035. However, mortality due to multidrug-resistant tuberculosis (MDR-TB) remains particularly high. Globally, almost 20% of patients started on MDR-TB treatment die during the course of treatment every year. We set out to examine the risk factors for mortality among a cohort of patients diagnosed with MDR-TB in Uganda.

Methods

We conducted a case-control study nested within the national MDR-TB cohort. We defined cases as patients who died from any cause during the course of MDR-TB treatment. We selected two controls for each case from patients alive and on MDR-TB treatment at the time that the death occurred (incidence-density sampling). We matched the cases and controls on health facility at which they were receiving care. We performed conditional logistic regression to identify the risk factors for mortality.

Results

Data from 198 patients (66 cases and 132 controls) started on MDR-TB treatment from January 1 to December 31, 2016, was analyzed for this study. Cases were similar to controls in age/sex distribution, occupation and history of TB treatment. However, cases were more likely to be HIV infected while controls were more likely to have attained secondary level education. On multivariate regression analysis, co-infection with HIV (aOR 1.9, 95% CI [1.1–4.92] p = 0.05); non-adherence to MDR-TB treatment (aOR 1.92, 95% CI [1.02–4.83] p = 0.04); age over 50 years (aOR 3.04, 95% CI [1.13–8.20] p = 0.03); and having no education (aOR 3.61, 95% CI [1.1–10.4] p = 0.03) were associated with MDR-TB mortality.

Conclusion

To mitigate MDR-TB mortality, attention must be paid to provision of social support particularly for older persons on MDR-TB treatment. In addition, interventions that support treatment adherence and promote early detection and management of TB among HIV infected persons should also be emphasized.
Literature
2.
go back to reference Ministry of Health U. Ministry of Health Uganda National Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis National Tuberculosis and Leprosy Program. 2016. Ministry of Health U. Ministry of Health Uganda National Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis National Tuberculosis and Leprosy Program. 2016.
3.
go back to reference WHO. Global Tuberculosis Report 2020. 2020. WHO. Global Tuberculosis Report 2020. 2020.
4.
go back to reference Uganda Ministry of Health. The Republic of Uganda The Uganda National Tuberculosis Prevalence Survey, 2014-2015 Survey Report 2015. Uganda Ministry of Health. The Republic of Uganda The Uganda National Tuberculosis Prevalence Survey, 2014-2015 Survey Report 2015.
5.
go back to reference Uganda Ministry of Health. NTLP Annual Report. 2019. Uganda Ministry of Health. NTLP Annual Report. 2019.
6.
8.
go back to reference Pradipta IS, Van’T Boveneind-Vrubleuskaya N, Akkerman OW, Alffenaar JWC, Hak E. Treatment outcomes of drug-resistant tuberculosis in the Netherlands, 2005-2015. Antimicrob Resist Infect Control. 2019;8(1):1–12.CrossRef Pradipta IS, Van’T Boveneind-Vrubleuskaya N, Akkerman OW, Alffenaar JWC, Hak E. Treatment outcomes of drug-resistant tuberculosis in the Netherlands, 2005-2015. Antimicrob Resist Infect Control. 2019;8(1):1–12.CrossRef
9.
go back to reference Adams L, Bergstrom K, Bleed D, Colvin C, Eckert E. Compendium of indicators for monitoring and evaluating national tuberculosis programs. PoplineOrg; 2004. Adams L, Bergstrom K, Bleed D, Colvin C, Eckert E. Compendium of indicators for monitoring and evaluating national tuberculosis programs. PoplineOrg; 2004.
11.
go back to reference Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM. Treatment outcomes of multidrug-resistant tuberculosis: A systematic review and meta-analysis. PLoS One. 2009;4:1.CrossRef Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM. Treatment outcomes of multidrug-resistant tuberculosis: A systematic review and meta-analysis. PLoS One. 2009;4:1.CrossRef
12.
go back to reference Palacios E, Franke M, Muñoz M, Hurtado R, Dallman R, Chalco K, Guerra D, Mestanza L, LLaro K, Bonilla C, Sebastian J, Bayona J, Lygizos M, Anger H, Shin S. HIV-positive patients treated for multidrug-resistant tuberculosis: clinical outcomes in the HAART era. Int J Tuberc Lung Dis. 2012;16(3):348–54. https://doi.org/10.5588/ijtld.11.0473.CrossRefPubMed Palacios E, Franke M, Muñoz M, Hurtado R, Dallman R, Chalco K, Guerra D, Mestanza L, LLaro K, Bonilla C, Sebastian J, Bayona J, Lygizos M, Anger H, Shin S. HIV-positive patients treated for multidrug-resistant tuberculosis: clinical outcomes in the HAART era. Int J Tuberc Lung Dis. 2012;16(3):348–54. https://​doi.​org/​10.​5588/​ijtld.​11.​0473.CrossRefPubMed
13.
go back to reference World Health Organization. Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy. Geneva: World Healh Organisation; 2017. World Health Organization. Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy. Geneva: World Healh Organisation; 2017.
14.
go back to reference Kaplan R, Hermans S, Caldwell J, Jennings K, Bekker LG, Wood R. HIV and TB co-infection in the ART era: CD4 count distributions and TB case fatality in Cape Town. BMC Infect Dis. 2018;18(1). Kaplan R, Hermans S, Caldwell J, Jennings K, Bekker LG, Wood R. HIV and TB co-infection in the ART era: CD4 count distributions and TB case fatality in Cape Town. BMC Infect Dis. 2018;18(1).
15.
go back to reference Yan S, Chen L, Wu W, FuZ, Zhang H, Li Z, FuC, Mou J, Xue J, Hu Y, Winston A. Early versus delayed antiretroviral therapy for HIV and tuberculosis co-infected patients: a systematic review and meta-analysis of randomized controlled trials. PLOS ONE. 2015;10(5):e0127645. Yan S, Chen L, Wu W, FuZ, Zhang H, Li Z, FuC, Mou J, Xue J, Hu Y, Winston A. Early versus delayed antiretroviral therapy for HIV and tuberculosis co-infected patients: a systematic review and meta-analysis of randomized controlled trials. PLOS ONE. 2015;10(5):e0127645.
16.
go back to reference Mitnick CD, Rodriguez CA, Hatton ML, Brigden G, Cobelens F, Grobusch MP, et al. Programmatic Management of Drug-Resistant Tuberculosis: an updated research agenda. PLoS One. 2016;11(5):1–16.CrossRef Mitnick CD, Rodriguez CA, Hatton ML, Brigden G, Cobelens F, Grobusch MP, et al. Programmatic Management of Drug-Resistant Tuberculosis: an updated research agenda. PLoS One. 2016;11(5):1–16.CrossRef
17.
go back to reference Kibret KT, Moges Y, Memiah P, Biadgilign S. Treatment outcomes for multidrug-resistant tuberculosis under DOTS-plus: a systematic review and meta-analysis of published studies. Infect Dis Poverty. 2017;6(1):1–8.CrossRef Kibret KT, Moges Y, Memiah P, Biadgilign S. Treatment outcomes for multidrug-resistant tuberculosis under DOTS-plus: a systematic review and meta-analysis of published studies. Infect Dis Poverty. 2017;6(1):1–8.CrossRef
20.
go back to reference Cutler DM, Lleras-Muney A. Education and health: evaluating theories and evidence. Natl Bur Econ Res. 2006;2006(3):805–11. Cutler DM, Lleras-Muney A. Education and health: evaluating theories and evidence. Natl Bur Econ Res. 2006;2006(3):805–11.
21.
go back to reference Ross CE, Wu C. The links between education and health. Am Sociol Rev. 2009;60(5):719–45.CrossRef Ross CE, Wu C. The links between education and health. Am Sociol Rev. 2009;60(5):719–45.CrossRef
22.
go back to reference UDHS. Uganda Demographic and Health Survey Key Indicators Report 2016. RoU. 2017. UDHS. Uganda Demographic and Health Survey Key Indicators Report 2016. RoU. 2017.
23.
go back to reference Wu J, Dalal K. Tuberculosis in Asia and the Pacific: the role of socioeconomic status and health system development. Int J Prev Med. 2012;3(1):8–16.PubMedPubMedCentral Wu J, Dalal K. Tuberculosis in Asia and the Pacific: the role of socioeconomic status and health system development. Int J Prev Med. 2012;3(1):8–16.PubMedPubMedCentral
25.
go back to reference Uganda Ministry of Health. Direct and Indirect costs due to Tuberculosis and proportion of Tuberculosis-affected households experiencing catastrophic costs due to TB in Uganda. 2019. Uganda Ministry of Health. Direct and Indirect costs due to Tuberculosis and proportion of Tuberculosis-affected households experiencing catastrophic costs due to TB in Uganda. 2019.
Metadata
Title
Risk factors for mortality among patients diagnosed with multi-drug resistant tuberculosis in Uganda- a case-control study
Authors
Enock Kizito
Joseph Musaazi
Kenneth Mutesasira
Fred Twinomugisha
Helen Namwanje
Timothy Kiyemba
Debora B. Freitas Lopez
Nicholas Sebuliba Nicholas
Abel Nkolo
Estella Birabwa
Seyoum Dejene
Stella Zawedde-Muyanja
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2021
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-021-05967-2

Other articles of this Issue 1/2021

BMC Infectious Diseases 1/2021 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.